期刊
LEUKEMIA
卷 35, 期 2, 页码 389-403出版社
SPRINGERNATURE
DOI: 10.1038/s41375-020-0864-3
关键词
-
资金
- Ministry of Science, Research and the Art (MWK), Baden-Wurttemberg, Germany [D.4268]
- Baustein program, University of Ulm, Germany [3.2]
- Italian Foundation for Cancer Research (AIRC)
- Physician Scientists Grant from the Helmholtz Zentrum Munchen
- DFG [SFB 1074]
TET1 is highly expressed in T-ALL and plays a crucial role in promoting leukemic growth by maintaining global 5-hydroxymethylcytosine (5hmC) marks to regulate cell cycle, DNA repair genes, and oncogenes. PARP enzymes participate in establishing H3K4me3 marks at the TET1 promoter and PARP inhibitor Olaparib can antagonize the growth-promoting role of TET1 in T-ALL by inducing loss of 5hmC marks.
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological cancer characterized by skewed epigenetic patterns, raising the possibility of therapeutically targeting epigenetic factors in this disease. Here we report that among different cancer types, epigenetic factor TET1 is highly expressed in T-ALL and is crucial for human T-ALL cell growth in vivo. Knockout of TET1 in mice and knockdown in human T cell did not perturb normal T-cell proliferation, indicating that TET1 expression is dispensable for normal T-cell growth. The promotion of leukemic growth by TET1 was dependent on its catalytic property to maintain global 5-hydroxymethylcytosine (5hmC) marks, thereby regulate cell cycle, DNA repair genes, and T-ALL associated oncogenes. Furthermore, overexpression of the Tet1-catalytic domain was sufficient to augment global 5hmC levels and leukemic growth of T-ALL cells in vivo. We demonstrate that PARP enzymes, which are highly expressed in T-ALL patients, participate in establishing H3K4me3 marks at the TET1 promoter and that PARP1 interacts with the TET1 protein. Importantly, the growth related role of TET1 in T-ALL could be antagonized by the clinically approved PARP inhibitor Olaparib, which abrogated TET1 expression, induced loss of 5hmC marks, and antagonized leukemic growth of T-ALL cells, opening a therapeutic avenue for this disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据